Abbvie Inc. V. Teva Pharmaceuticals, Inc. - 1:23-cv-00133

Abbvie Inc. V. Teva Pharmaceuticals, Inc. (Case No. 1:23-cv-00133), filed on Feb 3, 2023 in the District Court, D. Delaware involving patent infringement. This case involves patent infringement claims between the parties. Explore details about the litigants, key filings, and major docket updates.

Case Details

Case Number
1:23-cv-00133
Filing Date
Feb 3, 2023
Cause of Action
Patent Infringement
Status
-
Court
District Court, D. Delaware
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

Parties Involved

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Teva Pharmaceutical Industries Ltd. -
AbbVie Inc. -

Patents Involved

This case involves 2 patents, each of which is central to the dispute. These patents may be subject to claims of infringement, challenges to their validity, or other issues concerning their scope and enforcement.

Application NumberPatent Number
-US11045470B2
-US10881659B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Feb 3, 2023Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by AbbVie Inc. (twk) (Entered: 02/03/2023)PACER Document
Feb 3, 2023Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,881,659 B2; 11,045,470 B2. (twk) (Entered: 02/03/2023)PACER Document
Feb 3, 2023Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: December 22, 2022. Date NDA Holder Received Notice: December 22, 2022. Date of Expiration of U.S. Patent No. 10,881,659: March 14, 2034. Date of Expiration of U.S. Patent No. 11,045,470: March 14, 2034. Hatch-Waxman Regulatory Exclusivity Deadline: January 23, 2026. (twk) (Entered: 02/03/2023)PACER Document
Feb 3, 2023Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) (Entered: 02/03/2023)PACER Document
Feb 3, 2023COMPLAINT FOR PATENT INFRINGEMENT filed against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4059778.) - filed by AbbVie Inc. (Attachments: # 1 Exhibit A-B, # 2 Civil Cover Sheet)(twk) (Entered: 02/03/2023)PACER Document
Apr 20, 2023SO ORDERED Granting 6 Stipulation and Proposed Order (*Party Teva Pharmaceutical Industries Ltd. terminated) (*Reset Answer Deadlines: Teva Pharmaceuticals, Inc. answer due 6/5/2023). Signed by Judge Richard G. Andrews on 4/20/2023. (nms) (Entered: 04/20/2023)PACER Document
Apr 20, 2023STIPULATION and [Proposed] Order Regarding Teva Defendants by AbbVie Inc.. (Tigan, Jeremy) (Entered: 04/20/2023)PACER Document
Feb 3, 2023No Summons Issued. (twk)PACER Document
Feb 8, 2023Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb)PACER Document